Search results
Results from the WOW.Com Content Network
Intravenous sugar solution, also known as dextrose solution, is a mixture of dextrose (glucose) and water. [1] It is used to treat low blood sugar or water loss without electrolyte loss. [ 2 ] Water loss without electrolyte loss may occur in fever , hyperthyroidism , high blood calcium , or diabetes insipidus . [ 2 ]
Extravasation is the leakage of intravenously (IV) infused, and potentially damaging, medications into the extravascular tissue around the site of infusion. The leakage can occur through brittle veins in the elderly, through previous venipuncture access, or through direct leakage from wrongly positioned venous access devices.
As a medication, insulin is any pharmaceutical preparation of the protein hormone insulin that is used to treat high blood glucose. [6] Such conditions include type 1 diabetes, type 2 diabetes, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. [6]
A new study shows that GLP-1 injectables, including Ozempic, Wegovy and Saxenda, could cause severe digestive complications. A new study […] The post Weight loss drugs like Ozempic, Wegovy may ...
In the early days of insulin treatment for type 1 diabetes there was much debate as to whether strict control of hyperglycaemia would delay or prevent the long-term complications of diabetes. The work of Pirart [ 50 ] suggested that microvascular complications of diabetes were less likely to occur in individuals with better glycaemic control.
Dextrose 5% and 10% come in IV bag and syringe form, and are mainly used in infants and to provide a fluid medium for medications. Dextrose 25% and 50% are heavily necrotic due to their hyperosmolarity, and should only be given through a patent IV line – any infiltration can cause massive tissue necrosis.
The main risk factor is a history of diabetes mellitus type 2. [4] Occasionally it may occur in those without a prior history of diabetes or those with diabetes mellitus type 1. [3] [4] Triggers include infections, stroke, trauma, certain medications, and heart attacks. [4] Other risk factors: Lack of sufficient insulin (but enough to prevent ...
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.